Please login to the form below

Not currently logged in
Email:
Password:

Sagent appoints Michael Fekete to board

Will support growth of injectables firm following initial public offering

Sagent Pharmaceuticals has appointed Michael Fekete as the sixth member of its board of directors.

Fekete is currently director at both pharma firm DFB Pharmaceuticals and Symetis SA, which creates minimally invasive heart valve replacement therapies for patients suffering from heart valve diseases.

He is a corporate adviser specialising in capital markets, mergers and acquisitions and general corporate strategy and has experience at Oppenheimer & Co and L F Rothschild & Co.

Illinois, US-based injectable specialist Sagent will benefit from his advice as it looks to expand following its successful initial public offering, which Fekete assisted in an advisory role.

“Mike's experience and skill set will be particularly valuable to us as we continue to drive our growth,” said Jeffrey Yordon, founder, CEO and chairman of the board of Sagent.

“We look forward to his contribution to the board of directors and his involvement with senior management of the company."

16th July 2013

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Cello Health

Cello Health are expert navigators, helping healthcare clients uncover hidden insights, explore scientific options and make difficult strategic choices...

Latest intelligence

Precision paediatrics: Treating patients with CAR-T
Dr Stuart Adams specialises in using T-cell therapy to treat paediatric patients at Great Ormond Street Hospital. Here, he explains what it was like to develop and deliver a groundbreaking...
What does it mean to be an agile organisation
We spoke with Philip Atkinson to learn how healthcare and pharmaceutical companies can rapidly respond to changes in the market....
Battling breast cancer with precision medicine (Part 2)
Dr Mark Moasser treated breast cancer survivor Laura Holmes-Haddad (interviewed in part one) with an innovative precision medicine, which at the time was yet to be approved. Here he gives...

Infographics